Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 12
ctDNA to Inform Adjuvant Therapy and the CIRCULATE Trial
Medical professionals explore methods for integrating circulating tumor DNA results with radiographic and pathologic findings to optimize patient care.
- How do you factor ctDNA into treatment selection and management?
- How do you integrate ctDNA with radiographic or pathologic correlates?
Recent Videos
Related Content
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024Article
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
